Pulmonx (LUNG) Revenue & Revenue Breakdown
Pulmonx Revenue Highlights
Latest Revenue (Y)
$68.67M
Latest Revenue (Q)
$20.39M
Main Geography (Y)
UNITED STATES
Pulmonx Revenue by Period
Pulmonx Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $68.67M | 27.98% |
| 2022-12-31 | $53.66M | 10.84% |
| 2021-12-31 | $48.42M | 47.91% |
| 2020-12-31 | $32.73M | 0.42% |
| 2019-12-31 | $32.59M | 62.94% |
| 2018-12-31 | $20.00M | - |
Pulmonx generated $68.67M in revenue during NA 2023, up 27.98% compared to the previous quarter, and up 343.31% compared to the same period a year ago.
Pulmonx Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $20.39M | -1.91% |
| 2024-06-30 | $20.78M | 10.23% |
| 2024-03-31 | $18.85M | -2.20% |
| 2023-12-31 | $19.28M | 9.11% |
| 2023-09-30 | $17.67M | 2.76% |
| 2023-06-30 | $17.19M | 18.29% |
| 2023-03-31 | $14.54M | -5.77% |
| 2022-12-31 | $15.43M | 14.24% |
| 2022-09-30 | $13.50M | -3.21% |
| 2022-06-30 | $13.95M | 29.35% |
| 2022-03-31 | $10.79M | -21.32% |
| 2021-12-31 | $13.71M | 3.37% |
| 2021-09-30 | $13.26M | 8.67% |
| 2021-06-30 | $12.20M | 32.01% |
| 2021-03-31 | $9.24M | -5.96% |
| 2020-12-31 | $9.83M | -7.37% |
| 2020-09-30 | $10.61M | 188.92% |
| 2020-06-30 | $3.67M | -57.38% |
| 2020-03-31 | $8.62M | -16.71% |
| 2019-12-31 | $10.35M | 13.65% |
| 2019-09-30 | $9.10M | 23.59% |
| 2019-06-30 | $7.37M | 12.08% |
| 2019-03-31 | $6.57M | - |
Pulmonx generated $20.39M in revenue during Q3 2024, up -1.91% compared to the previous quarter, and up 118.57% compared to the same period a year ago.
Pulmonx Revenue Breakdown
Pulmonx Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| EMEA | $19.34M | $18.15M | $19.88M | $13.81M |
| Other International Geographical Areas | $399.00K | $155.00K | $128.00K | $49.00K |
| UNITED STATES | $45.92M | $32.49M | $24.99M | $16.19M |
| Asia Pacific | $3.02M | $2.87M | $3.41M | $2.69M |
Pulmonx's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (66.86%), EMEA (28.16%), Asia Pacific (4.40%), and Other International Geographical Areas (0.58%).
Quarterly Revenue by Country
| Country | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMEA | $5.13M | $5.96M | $5.12M | $4.64M | $4.85M | $5.31M | $4.53M | $5.13M | $4.41M | $4.57M | $4.05M | $5.48M | $5.61M | $4.75M | $4.04M | $4.11M | $4.44M |
| Other International Geographical Areas | $145.00K | $139.00K | $171.00K | $96.00K | $164.00K | $68.00K | $71.00K | $57.00K | $58.00K | $40.00K | $79.00K | $37.00K | $12.00K | - | $10.00K | - | - |
| UNITED STATES | $13.84M | $13.88M | $12.87M | $13.72M | $11.84M | $11.02M | $9.34M | $9.46M | $8.40M | $8.62M | $6.01M | $7.28M | $6.86M | $6.57M | $4.29M | $4.87M | $5.34M |
| Asia Pacific | $1.28M | $802.00K | $698.00K | $821.00K | $814.00K | $792.00K | $596.00K | $786.00K | $637.00K | $724.00K | $719.00K | $872.00K | $756.00K | $875.00K | $911.00K | $841.00K | $827.00K |
Pulmonx's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (67.87%), EMEA (25.16%), Asia Pacific (6.26%), and Other International Geographical Areas (0.71%).
Pulmonx Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ITGR | Integer | $1.60B | $746.27M |
| CNMD | CONMED | $1.24B | $316.70M |
| LIVN | LivaNova | $1.15B | $318.11M |
| INGN | Inogen | $315.66M | $88.83M |
| AXGN | AxoGen | $159.01M | $48.64M |
| KIDS | OrthoPediatrics | $148.73M | $52.80M |
| SIBN | SI-BONE | $138.89M | $40.34M |
| SRDX | Surmodics | $126.08M | $30.34M |
| RXST | RxSight | $89.08M | $45.41M |
| LUNG | Pulmonx | $68.67M | $20.39M |
| IRMD | IRadimed | $65.56M | $18.33M |
| NPCE | NeuroPace | $65.42M | $21.06M |
| APYX | Apyx Medical | $52.35M | $16.02M |
| OFIX | Orthofix Medical | $100.00K | $198.62M |